COBI (Compass Biotechnologies) - released news over that past two trading sessions regarding their new management leadership and their speaking engagement with what is reportedly the LARGEST North American generic medicines strategy event...
Compass Biotechnologies Inc Invited to Speak at The World Generic Medicines Congress Americas 2011
EDMONTON, May 31, 2011 /PRNewswire/ - Compass Biotechnologies (OTCBB:COBI) is pleased to announce that Dr. Joseph Sinkule President and COO of Compass Biotech has been invited to speak at the fourth annual World Generic Medicines Congress Americas 2011 to be held this fall from November 12 - November 15 at the Westin Grand, Washington D.C.
The Congress is the largest of its kind within the Generics Industry and for the first time this year is expanding to include the World Biosimiliars Summit to help focus on the key challenges facing the commercialization of the soon to be multiple billion dollar biosimiliar US and global markets.
The meeting unites a speaker platform of the highest seniority with all stakeholders in the industry and allows participants to position their products and services in front of decision makers from major Pharma manufacturers and large biotech companies. Dr. Sinkule who will speak on "Strategies and Opportunities for Smaller and Niche Generic Companies"
Dr Sinkule commented "It is indeed an honour and a privilege to be invited to speak at such a timely and prestigious event that will provide excellent exposure for the Company. Further, we feel it speaks to the acceptance of our approach to this increasingly important and growing market sector".
ABOUT COMPASS BIOTECHNOLOGIES INC. (OTCBB: COBI) www.compassbio.net
Compass Biotechnologies is a publically-traded specialty biopharmaceutical company (COBI:OB) with headquarters in Edmonton, Alberta. The mission of Compass is to develop generic, biosimiliar and bio-better drug products that can bring revenue generation to the company in a near term fashion. A recent agreement with PanGen to supply protein active pharmaceutical ingredients to facilitate this mission was announced recently. Further Compass under a license from the National Institutes of Health (NIH) has opportunities to develop products from the platform technology available and or sub licensee these opportunities to other interested partners. Compass Biotech also owns a subsidiary company called C-Pharma Inc.
ABOUT C-PHARMA INC. www.c-pharma.net
C-Pharma's technology encompasses the use of recombinant DNA technology to manufacture virus like particles (VLPs). These VLPs can be engineered to incorporate various viral and non-viral antigens for use as vaccines against many different types of targets such as Hepatitis C. The recombinant antigens presented in the context of a VLP carrier system are much more immunogenic than the antigen alone, and this carrier is so powerful that the subsequent vaccine may not require the use of immune adjuvants. C-Pharma is using the technology to develop a Hepatitis C vaccine to prevent hepatitis C viral infection of liver hepatocytes. The Company is also pursuing a revenue generation strategy by commercializing generic therapeutic drugs (ribavirin and interferon alpha) for use in the Hepatitis C market.
----------------------------------------------------
On Friday, the Company released news updating shareholders about their new President and CEO - Dr. Joseph Sinkule - as well as a additional information about the growth potential of the generic drug market.
Per the news announcement, Dr. Sinkule is a pharmaceutical and biotech product development expert who:
Has a solid foundation of management and product development skills, being a seasoned pharmaceutical executive with over 30 years of academic and industry experience.
Has led the strategic development efforts of multiple drugs and biologics including manufacturing and scale-up, quality control, non-clinical studies, Phase I-Phase III clinical trials, regulatory affairs, and the project management and budgeting associated with the commercialization efforts of life-saving medical products.
The global market for biosimilar products has the potential to exceed Five Billion in sales within the next few years as current blockbuster drugs with global sales of over Twenty Billion, have lost their patent protection.
Hence, the market potential could be MASSIVE.
Further Dr. Sinkule will also head up C-Pharma Inc's, (a Compass Bio subsidiary company), hepatitis drug development program, which is worth an additional Two Billion plus a year.
------------------------------------------
Source Lyquid Tycoon
